# Tony Kingsley

> Tony Kingsley is a biopharmaceutical executive who runs Stablix, Inc., a New York biotech betting that you can treat disease by protecting proteins instead of destroying them. He took the CEO seat in February 2022 after a career of running one drug company after another - Scholar Rock, TARIS Bio, The Medicines Company - and heading global commercial at Biogen, with a McKinsey partnership and a stint in medical devices before that. In July 2025 he joined the board of Indivior. He holds a Dartmouth degree and a Harvard MBA.

- **Role:** Chief Executive Officer & Director at Stablix, Inc.
- **Organizations:** Stablix, Inc., Indivior PLC, Scholar Rock, TARIS Bio, The Medicines Company, Biogen, Hologic, Cytyc Corporation, McKinsey & Company
- **Nationality:** American
- **Education:** Undergraduate degree, Dartmouth College, MBA, Harvard Business School
- **Known for:** Named CEO of Stablix, Inc. in February 2022 to build out its targeted protein stabilization platform, Led TARIS Bio as President & CEO through its acquisition by Janssen/Johnson & Johnson at the end of 2019, Ran global commercial operations at Biogen as Executive Vice President from 2010 to 2015

## Career timeline

- **Early career** — Partner at McKinsey & Company
- **2006-2009** — SVP & GM of gynecological surgical products at Hologic; earlier division president, diagnostic products at Cytyc Corporation
- **2010-2015** — Executive Vice President, Global Commercial at Biogen
- **2016-2018** — President & Chief Operating Officer of The Medicines Company
- **2018-2019** — President & CEO of TARIS Bio, through its acquisition by Janssen/J&J at the end of 2019
- **2020-2021** — President & CEO of Scholar Rock (effective August 1, 2020)
- **2022** — Named CEO of Stablix, Inc. (February 14, 2022)
- **2025** — Appointed Independent Non-Executive Director on the board of Indivior PLC (effective July 1, 2025)

## Achievements

- Named CEO of Stablix, Inc. in February 2022 to build out its targeted protein stabilization platform
- Led TARIS Bio as President & CEO through its acquisition by Janssen/Johnson & Johnson at the end of 2019
- Ran global commercial operations at Biogen as Executive Vice President from 2010 to 2015
- Served as President & COO of The Medicines Company
- Appointed to the Indivior PLC board of directors in 2025
- Rose to partner at McKinsey & Company

## Latest updates

- **2025-07** — Appointed Independent Non-Executive Director on the board of Indivior PLC, effective July 1, 2025.
- **2022-02** — Named Chief Executive Officer of Stablix, Inc.

## Links

- Website: https://stablix.com
- LinkedIn: http://www.linkedin.com/in/tony-kingsley-01665422
- Twitter/X: https://twitter.com/StablixInc

---

Profile page: https://yespress.io/tony-kingsley
Published by YesPress — https://yespress.io
Last updated: 2026-07-07